A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD — Stella

Recruiting

Back to COPD (Chronic Obstructive Pulmonary Disease) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Joincare Pharmaceutical Group Industry Co., Ltd

Enrollment target

~120 participants

Started

November 2025

Primary completion

September 2026

Age range

40 Years – 80 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov